Leptin regulates energy homoeostasis through central and peripheral mechanisms. Initial steps in leptin action include signalling through a cytokine-like receptor which activates the JAK/STAT pathway. We investigated whether the metabolic effects of leptin in muscle could be mediated by the AMP-activated protein kinase (AMP kinase). Through studies involving leptin injection intrahypothalamically or intravenously, as well as incubation of soleus muscle or cultured muscle cells with leptin, we determined that leptin stimulates fatty acid oxidation in skeletal muscle by activating AMP kinase. Leptin exerts this effect directly at the level of muscle and also through the hypothalamic sympathetic nervous system, specifically engaging α-adrenergic receptors in muscle. This represents a novel and important pathway mediating leptin's metabolic actions.
Introduction
Leptin is a hormone secreted by adipocytes that plays a pivotal role in regulation of food intake, energy expenditure and neuroendocrine function [1] . Leptin stimulates fatty acid oxidation [2] and glucose uptake [3] [4] [5] and prevents lipid accumulation in non-adipose tissues, which can lead to functional impairments (lipotoxicity) [6] . The signalling pathways mediating leptin's metabolic effects remain undefined. The 5 -AMP-activated protein kinase (AMPK) potently stimulates fatty acid oxidation in muscle by inhibiting acetyl-CoA carboxylase (ACC) activity [7, 8] . AMPK is a heterotrimeric enzyme that is conserved from yeast to humans and functions as a 'fuel gauge' to monitor cellular energy status [7] . We found that leptin selectively stimulates phosphorylation and activation of the α2 catalytic subunit of AMPK (α2 AMPK) in skeletal muscle. Early activation of AMPK occurs by leptin action directly on muscle, whereas later activation depends on leptin action through the hypothalamic-sympathetic nervous system axis. In parallel with AMPK activation, leptin suppresses ACC activity, thereby stimulating fatty acid oxidation in muscle. Blocking AMPK activation inhibits leptin-stimulated phosphorylation of ACC. Thus, our data suggest that AMPK is a mediator of leptin's effects on fatty acid metabolism in muscle.
Leptin has metabolic effects in skeletal muscle, independent of food intake of glucose and fatty acid utilization, and is one of the primary tissues responsible for insulin resistance in obesity and Type 2 diabetes [9] . Increased lipid stores in non-adipose tissues such as muscle are linked to functional impairments, called 'lipotoxicity', which lead to insulin resistance and impaired insulin secretion [6] . Although the lipid factor which causes lipotoxicity is not identified, involvement of fatty acyl-CoA or diacylglycerol, acting through a form of protein kinase C, is suspected [10] . Interestingly, as well as in obesity, insulin resistance often is present in lipodystrophy, in which fat tissue is absent [11, 12] . In this rare human disorder, excess lipid accumulates in tissues such as the liver and skeletal muscle, and patients suffer from severe insulin-resistant diabetes. Genetically engineered experimental animals show the same pathophysiology [13, 14] . Recent studies demonstrate that treatment with leptin decreases lipid accumulation in non-adipose tissues and improves severe diabetes in lipodystrophy patients as well as experimental animals [11, 12, 15] .
Leptin is secreted by adipocytes and signals nutritional information to regulatory centres in the hypothalamus and other brain regions [1] . Treatment with the hormone in animals suppresses food intake and increases energy expenditure, accompanied by a reduction in the amount of adipose tissue and intracellular lipid in skeletal muscle, liver and pancreatic β cells [1, 6, 16, 17] . Decreases in the amount of lipid in these tissues is evident at doses that do not affect weight, suggesting that the effect of leptin may not only be a consequence of its ability to reduce food intake [1, 15, 18] .
It is now evident that many of the effects of leptin on metabolism, as well as food intake, are exerted in the hypothalamus [1] . Injection of a low dose of leptin into the medial hypothalamus, which expresses the leptin receptor (Ob-Rb) abundantly, increases basal glucose uptake by skeletal muscle, brown adipose tissue and heart [3] [4] [5] .
Hypothalamic injection of leptin further enhances insulininduced glucose uptake in these tissues within 6 h of the injection, but not in white adipose tissue [3] [4] [5] . Intravenous (iv) and intracerebroventricular injection of leptin stimulates sympathetic nerve activity in these tissues [19, 20] , and these effects of leptin on glucose uptake, are blunted by a sympathetic nerve-blocking agent (guanethidine), a β-adrenergic antagonist (propranolol) or by surgical sympathetic denervation [4, 5] . The results suggest that leptin acutely increases glucose uptake and insulin sensitivity in some peripheral tissues through the hypothalamic-sympathetic nervous system axis.
However, the long-form leptin receptor (Ob-Rb), which is essential for leptin's effects on food intake and metabolism [21] , is expressed not only in the hypothalamus but also in many peripheral tissues [21] [22] [23] [24] [25] [26] [27] [28] [29] . Direct effects of leptin are proposed in lymphocytes [25] , macrophages [26] , hepatocytes [30] , pancreatic islets [6] , chromaffin cells [31] , adipocytes [32] [33] [34] , skeletal muscle [2] , gonads [27, 29] , vasculature [28, 29] and other peripheral tissues [29] . In skeletal muscle, leptin stimulates fatty acid oxidation and reduces fatty acid esterification directly in muscle in vitro [2] . However, signalling pathways that mediate the metabolic effects of leptin remains undefined.
Leptin activates AMPK in muscle in vivo
AMPK is a regulator of cellular metabolism in response to changes in the energy status of the cells [7, 8] . AMPK shuts down anabolic pathways and activates catabolic pathways in response to a fall in the ATP/AMP ratio by phosphorylating key enzymes of intermediate metabolism [7, 8] . Recent studies demonstrate that activation of AMPK participates in the contraction-induced glucose uptake and fatty acid oxidation in muscle [8, 35, 36] . AMPK is also involved in hypoxiainduced glucose uptake in muscle [36] .
We examined AMPK activity in skeletal muscle after intrahypothalamic (ihp) and iv injection of leptin in freemoving FVB mice [37] . Ihp injection of leptin (1 ng) increased the activity of α2 AMPK in soleus muscle ( Figure 1 ). The effect peaked with a 3-fold stimulation at 1 h and was sustained for up to 6 h. In contrast, iv leptin (1 mg/kg of body weight) produced a biphasic response in α2 AMPK activity, with a 2-fold rise at about 15 min, a return to the baseline by 60 min, and a second 2-fold elevation by 6 h ( Figure 1A ). α1 AMPK activity did not change in soleus muscle after iv or ihp injection of leptin (results not shown).
A lower dose of leptin (50 µg/kg; iv), which is closer to the physiological range, also stimulated AMPK activity in muscle at both 15 and 6 h after injection [37] . Notably, db/db mice, which lack the long-form leptin receptor, Ob-Rb, did not show any stimulation of AMPK, even with a high dose of leptin (1 mg/kg). The effect of iv leptin on the activation of α2 AMPK was more pronounced in red (slow twitch, oxidative) skeletal muscles [37] , which have higher rates of fatty acid oxidation, than in white (fast twitch, glycolytic) muscles. Similarly, ihp injection of leptin stimulated α2 AMPK activity preferentially in soleus and red gastrocnemius [37] . These results indicate that iv and ihp leptin activate α2 AMPK in red muscle through Ob-Rb.
AMPK in skeletal muscle is activated by leptin directly and through the hypothalamic-sympathetic nervous system axis
The sympathetic nervous system is an important regulator that produces leptin's effects [1, 4, 5, 19, 20] . Therefore, we examined whether leptin-induced activation of AMPK in muscle is mediated by the sympathetic nervous system, using pharmacological adrenergic blockade and two kinds of surgical denervation of hindlimb [37] . Denervation of the sciatic nerve, which primarily impairs motor innervation, decreased the total catecholamine content to 62% of the contralateral, intact soleus muscle. Denervation of the sciatic, femoral and obturator nerves, which blocks both sympathetic and motor innervation, decreased catecholamine content to 6% of the control content.
Denervation of all three nerves blocked the ability of ihp leptin or iv leptin 6 h after injection to stimulate α2 AMPK in soleus muscle [37] . But α2 AMPK activation at 15 min after iv leptin, and after iv 5-amino-4-imidazolecarboxamide riboside (AICAR), remained intact in denervated muscle [37] . By contrast, denervation of the sciatic nerve alone did not block leptin-induced activation of AMPK in soleus, despite a complete loss of motor function [37] . Thus leptin's effect on AMPK is independent of motor nerve activity. These findings indicate that AMPK activation at 6 h after both iv leptin and ihp leptin may be mediated by the sympathetic nerves that innervate muscle. In contrast, activation at 15 min after iv leptin does not involve the sympathetic nervous system and may be direct. In fact, we incubated soleus muscle ex vivo with leptin, and leptin at 1 and 10 nM increased α2 AMPK activity 2.0-and 2.8-fold at 30 min, respectively [37] .
To elucidate the pathways involved in the neurally mediated effects, we examined the impact of the α-adrenergic antagonist phentolamine on leptin-induced activation of α2 AMPK in soleus muscle [37] . Consistent with the results of surgical denervation, phentolamine in vivo abolished AMPK activation 6 h after iv leptin and ihp leptin, but not the early activation by iv leptin or the activation by AICAR [37] . Thus, the early effect of iv leptin may be direct, but the later effect depends on the α-adrenergic nervous system. This was confirmed by ex vivo studies. Soleus muscle incubated ex vivo with phenylephrine, an α-adrenergic agonist, showed stimulation of AMPK activity that equalled that of leptin [37] . In contrast, the β-adrenergic agonist, isopreterenol, had no effect. Leptin had no effect on AMPK activity in soleus muscle from db/db mice. Thus, the α-adrenergic, but not the β-adrenergic, pathway is involved in the sympatheticnerve-mediated effect of leptin on AMPK, and these effects are mediated through Ob-Rb.
Our data show that leptin activates α2 AMPK in red muscle through two distinct mechanisms: one involves the hypothalamus and the α-adrenergic pathway; the other is independent of the sympathetic nervous system and appears to be direct. In support of the first mechanism, peripheral leptin injection increases sympathetic nerve activity that innervates hindlimbs, with a time course that is consistent with the late activation of α2 AMPK in muscle after iv leptin [20] . Furthermore, AMPK can be activated by the stimulation of G q -coupled receptors, including α-adrenergic receptors [38] . α-Adrenergic receptors have important functions in muscle fibers, especially in red muscle [39] [40] [41] . These results support our conclusions that the delayed effects of peripheral leptin are through hypothalamic neurons that stimulate the α-adrenergic pathway to activate α2 AMPK in muscle. In contrast, the early effect is independent of sympathetic nerves and motor nerves, and can be induced directly in muscle incubated with leptin ex vivo.
Leptin appears to stimulate AMPK kinase (AMPKK) in muscle
AMPK is activated by AMP allosterically and by phosphorylation by AMPKK [7, 8] . AMPKK is also stimulated by AMPindependent as well as AMP-dependent pathways [42, 43] . To explore the mechanism of AMPK activation in response to leptin, we examined the effect of leptin on phosphorylation of the α subunit of AMPK and on AMP content in soleus muscle [37] . iv leptin increased phosphorylation of Thr-172 in the α subunit of AMPK [37] , which is essential for activation of AMPK, at both 15 min and 6 h after the injection ( Figure 1B) . Denervation did not block phosphorylation at 15 min but blocked it at 6 h ( Figure 1B) , indicating that the former effect is direct, whereas the later requires the hypothalamussympathetic nervous system axis. These results clearly suggest that leptin activates AMPK in muscle through AMPKK.
We further examined the AMP content in soleus muscle [37] . The AMP content of soleus muscle increased about 2-fold at 15 min after iv leptin, but not at 6 h after iv leptin or after ihp leptin. Neither ATP nor ADP changed in response to leptin, although ATP had a tendency to decrease at 15 min after iv leptin. Thus, AMPK activation at 15 min after iv leptin may result from increased concentrations of cellular AMP, but the activation mediated by the sympathetic nervous system does not involve detectable changes in AMP, ADP or ATP.
Leptin stimulates fatty acid oxidation in muscle through inhibition of ACC activity ACC, which is a target of AMPK, provides a pivotal step in fuel metabolism, as it links fatty acid and carbohydrate metabolism through the shared intermediate acetyl-CoA [44] . The β isoform of ACC (ACC-β), which is the predominant isoform in skeletal muscle, is an essential regulator of fatty acid oxidation [44] . ACC-β-knockout mice show increased oxidation of fatty acids in muscle and are lean [44] . Phosphorylation of ACC-β by AMPK leads to inhibition of ACC activity, a fall in malonyl-CoA content, and a subsequent increase in fatty acid oxidation by disinhibiting carnitine palmitoyltransferase 1 (CPT1) in skeletal muscle [7, 8, 44] . Thus AMPK, through inhibition of ACC, might mediate the effects of leptin on lipid metabolism in muscle.
To determine whether AMPK activation mediates leptin's effects on fatty acid metabolism, we examined the activity of ACC [37] . iv and ihp leptin suppressed ACC activity in soleus muscle by about 50%, which is comparable with inhibition by AICAR [37] . These effects are probably caused by phosphorylation of ACC by AMPK, as ACC phosphorylation in soleus muscle increased after iv leptin, whereas concentrations of ACC protein did not change. ACC phosphorylation 6 h after iv leptin was blocked by denervation of the sciatic, femoral and obturator nerves. Levels of ACC phosphorylation strongly correlated with AMPK phosphorylation [37] . In db/db mice, leptin did not stimulate phosphorylation of AMPK or ACC, indicating that these effects of leptin require Ob-Rb.
To determine whether the AMPK pathway is required for the effects of leptin on ACC phosphorylation, we blocked AMPK activation using a catalytically inactive α subunit of AMPK that has a dominant negative effect on AMPK activity [37] . Dominant negative AMPK [45] inhibited basal AMPK activity in H-2K b muscle cells [46] by 63%. Ob-Rb has been detected in H-2K b cells (P. Shepherd, personal communication), and these cells are highly responsive to insulin and AICAR [47] . Leptin induced AMPK activity 1.8-fold in control cells [37] . This effect was completely blocked by dominant negative AMPK, indicating a full dominant negative effect on leptin signalling through AMPK [37] . Dominant negative AMPK inhibited basal ACC phosphorylation by 35%. Leptin induced ACC phosphorylation 1.9-fold, and this effect was also blocked by dominant negative AMPK [37] . Thus, activation of AMPK is necessary for leptin to inhibit ACC.
The decrease in ACC activity caused by leptin suggests that malonyl-CoA production is suppressed, leading to stimulation of fatty acid oxidation by disinhibition of CPT1. To elucidate this, we measured fatty acid utilization and oxidation in muscle after iv injection of leptin in vivo [37] , by assessing the incorporation of [ 3 H]2-(R)-bromopalmitic acid and [
14 C]palmitic acid [48] . 2-(R)-Bromopalmitic acid, as well as palmitic acid, is incorporated into cells, and converted into bromopalmitoyl-CoA, but it cannot be metabolized further. In contrast, palmitic acid is metabolized; it is partly accumulated into lipids and the rest is exported from cells through the process of oxidation. Thus accumulation of 2-(R)-bromopalmitic acid and palmitic acid in tissues reflects the rate of fatty acid utilization and fatty acid incorporation into lipids, respectively [48] . The difference between the accumulated amount of 2-(R)-bromopalmitic acid and palmitic acid indicates the rate of fatty acid oxidation [48] .
iv leptin increased fatty acid utilization in soleus and red gastrocnemius muscle (3.2-and 3.9-fold, respectively) at 6 h, but not in white gastrocnemius muscle or extensor digitorum longus [37] . Fatty acid incorporation into storage lipids was not increased by leptin. However, leptin increased the rate of fatty acid oxidation 6.4-and 15.3-fold in soleus and red gastrocnemius muscles, respectively (Figure 2 ) [37] . Leptin activates AMPKK/AMPK in muscle via two distinct mechanisms: one is a direct effect of leptin and the other is mediated by the hypothalamic-sympathetic nervous system. Activation of AMPK phosphorylates and inhibits ACC activity. Leptin then inhibits malonyl-CoA synthesis, activating CPT1, thereby increasing mitochondria import and fatty acid oxidation in muscle.
This effect was abolished by denervation of the sciatic, femoral and obturator nerves (Figure 2 ), but not by denervation of the sciatic nerve alone [37] . Thus, leptin stimulates fatty acid oxidation in red muscle, and the effect at 6 h is mediated through the sympathetic nervous system.
Conclusions
Our findings indicate that leptin activates AMPK, and probably AMPKK, in muscle through two distinct mechanisms: one is a direct effect of leptin and another is mediated by the hypothalamic-sympathetic nervous system. Activation of AMPK by leptin phosphorylates and inhibits ACC, and results in potent stimulation of fatty acid oxidation in muscle (Figure 3) . Although leptin probably has many functional roles in central and peripheral tissues, a physiological role for leptin may be to protect non-adipose tissues from steatosis and lipotoxicity by preventing the up-regulation of lipogenesis and by increasing the oxidation of fatty acids. Recently, it has been demonstrated that the anti-diabetic drug metformin activates AMPK in the liver and muscle, and stimulates fatty acid oxidation in the liver and glucose uptake in muscle [49] . Metformin also increases AMPK activity in skeletal muscles of subjects with Type 2 diabetes [50] . Therefore, the AMPK pathway might provide targets for therapeutic agents to reduce lipotoxicity in obesity and Type 2 diabetes.
